<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0375410</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5127</journal-id>
<journal-id journal-id-type="nlm-ta">J Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pediatr.</journal-id>
<journal-title-group>
<journal-title>The Journal of pediatrics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3476</issn>
<issn pub-type="epub">1097-6833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27640358</article-id>
<article-id pub-id-type="pmc">5873956</article-id>
<article-id pub-id-type="doi">10.1016/j.jpeds.2016.08.032</article-id>
<article-id pub-id-type="manuscript">NIHMS817215</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenotype Differentiation of <italic>FOXG1</italic> and <italic>MECP2</italic> Disorders: A New Method for Characterization of Developmental Encephalopathies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Mandy</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adams</surname>
<given-names>Heather R.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seltzer</surname>
<given-names>Laurie E.</given-names>
</name>
<degrees>DO</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dobyns</surname>
<given-names>William B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paciorkowski</surname>
<given-names>Alex R.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>University of Buffalo School of Medicine, Buffalo, NY</aff>
<aff id="A2">
<label>2</label>Department of Neurology, University of Rochester Medical Center, Rochester, NY</aff>
<aff id="A3">
<label>3</label>Strong Epilepsy Center, University of Rochester Medical Center, Rochester, NY</aff>
<aff id="A4">
<label>4</label>Department of Neurology, University of Washington, Seattle, WA</aff>
<aff id="A5">
<label>5</label>Division of Medical Genetics, Department of Pediatrics, University of Washington, Seattle, WA</aff>
<aff id="A6">
<label>6</label>Center for Integrative Brain Research, Seattle Childrenâ€™s Research Institute, Seattle, WA</aff>
<aff id="A7">
<label>7</label>Departments of Pediatrics and Biomedical Genetics, University of Rochester Medical Center, Rochester, NY</aff>
<aff id="A8">
<label>8</label>Center for Neural Development and Disease, University of Rochester Medical Center, Rochester, NY</aff>
<author-notes>
<corresp id="FN1">Reprint requests: Alex R. Paciorkowski, MD, University of Rochester Medical Center Child Neurology, 601 Elmwood Ave., Rochester, NY 14642. <email>Alex_Paciorkowski@urmc.rochester.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>The authors declare no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>178</volume>
<fpage>233</fpage>
<lpage>240.e10</lpage>
<!--elocation-id from pubmed: 10.1016/j.jpeds.2016.08.032-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">To differentiate developmental encephalopathies by creating a novel quantitative phenotyping tool.</p>
</sec>
<sec id="S2">
<title>Study design</title>
<p id="P2">We created the Developmental Encephalopathy Inventory (DEI) to differentiate disorders with complex multisystem neurodevelopmental symptoms. We then used the DEI to study the phenotype features of 20 subjects with <italic>FOXG1</italic> disorder and 11 subjects with <italic>MECP2</italic> disorder.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">The DEI identified core domains of fine motor and expressive language that were severely impaired in both disorders. Individuals with <italic>FOXG1</italic> disorder were overall more severely impaired. Subjects with <italic>FOXG1</italic> disorder were less able to walk, had worse fine motor skills, more disability in receptive language and reciprocity, and had more disordered sleep than did subjects with <italic>MECP2</italic> disorder (<italic>P</italic> &lt; .05). Covariance, cluster, and principal component analysis confirmed a relationship between impaired awareness, reciprocity, and language in both disorders. In addition, abnormal ambulation was a first principal component for <italic>FOXG1</italic> but not for <italic>MECP2</italic> disorder, suggesting that impaired ambulation is a strong differentiating factor clinically between the 2 disorders.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">We have developed a novel quantitative developmental assessment tool for developmental encephalopathies and propose this tool as a method to identify and illustrate core common and differential domains of disability in these complex disorders. These findings demonstrate clear phenotype differences between <italic>FOXG1</italic> and <italic>MECP2</italic> disorders.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>